Considerations for preferential selection of interferon therapy: interferon is a drug with a high rate of sustained response, young patients with antiviral indications, expecting to have children in recent years, expecting to complete treatment in a short period of time, and patients with a strong antibody immune clearance response (low viral load, high ALT levels, and a high degree of liver inflammation) are preferentially recommended for interferon therapy. Considerations for preferential selection of nucleoside analogue therapy: Patients who do not respond to interferon therapy, or who cannot tolerate the adverse effects of interferon, or who are inconvenienced or unwilling to receive injectable dosing, or who have decreased compensatory capacity or liver decompensation, are given preference for treatment with nucleoside analogues. Considerations for choosing nucleoside analogue therapy: the strength of inhibition of viral replication and the rate of drug resistance are important reference indicators for choosing nucleoside analogue therapy. Patients with high viral load can choose drugs that inhibit the virus more strongly, and vice versa, choose drugs that inhibit the virus relatively strongly, and studies have proved that entecavir and telbivudine inhibit the virus more strongly, and lamivudine and adefovir are relatively weak. Secondly, prevention and reduction of drug resistance are important factors to be considered in choosing nucleoside analogues, and choosing drugs with strong potency, low drug resistance and high hepatitis B E antigen conversion rate is one of the important measures to prevent and reduce drug resistance. tebivudine has a rapid and strong viral inhibitory effect, high hepatitis B E antigen conversion rate, good safety and moderate price, suitable as a priority choice for hepatitis B E antigen positive patients, and at 6 months Efficacy evaluation will be performed to further optimize treatment based on treatment response. Patients with low viral load, especially hepatitis B E antigen-negative patients, can be treated with adefovir and have a low incidence of drug resistance in long-term treatment.